NCT00194740 - Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 1997

Study Completion Date

June 30, 2007

Conditions

Breast Neoplasm

Interventions

DRUG

Docetaxel

60 mg/m2, IV, day 1 of each 21 day cycle

DRUG

Vinorelbine

27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle

DRUG

Filgrastim

5 µg/kg/day s.c., to be administered days 2-21 of each cycle.

Trial Locations (1)

University of Washington/Seattle Cancer Care Alliance, Seattle